Skip to content
Open access · CC-BY via OpenAlex

A review of rapamycin in companion dogs

Jacob Ryave, Amanda Erickson Coleman

Journal of Veterinary Science · 2025 · ▲ 2 citations

Abstract

IMPORTANCE: Aging is a complex process mediated by highly interconnected cellular, molecular and systemic pathways with genetic, environmental, dietary and lifestyle inputs, among others. Pharmacologic manipulation of aging’s molecular and cellular pathways—including those mediated by the mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR)—is an important ongoing area of study. OBSERVATIONS: Inhibition of mTOR has been associated with lifespan extension and delayed or slowed age-related pathologies in several laboratory species, with cited mechanisms including improved autophagy(definition), improved proteostasis(definition), and reduced mRNA translation, among others. The effects of the mTOR inhibitor rapamycin on longevity in non-laboratory species is an area of emerging study, and our understanding of mTOR signaling pathways and their effects on aging continues to evolve. In people, owing to its dose-dependent immunomodulatory effects, rapamycin is currently approved as an anti-cancer agent and for prevention of organ transplant rejection or restenosis of vascular stents. Its potential use as an intervention to increase life- and healthspan(definition) in companion dogs is an area of active research. CONCLUSIONS AND RELEVANCE: Rapamycin is a promising manipulator of multiple cellular and molecular telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition). The positive results of longevity studies in laboratory species have paved the way for similar studies of rapamycin in non-human primates and companion veterinary species. The results of these and ongoing studies that evaluate the effects of mTOR inhibition for disease treatment or longevity promotion will facilitate greater understanding of the aging process and clinically meaningful ways to leverage relevant pathways.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.4142/jvs.25219
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Ryave, J., &amp; Coleman, A.E. (2025). A review of rapamycin in companion dogs. <em>Journal of Veterinary Science</em>. https://doi.org/10.4142/jvs.25219
Vancouver
Ryave J, Coleman AE. A review of rapamycin in companion dogs. Journal of Veterinary Science. 2025. doi:10.4142/jvs.25219.
BibTeX
@article{jacob2025Arevie, title = {A review of rapamycin in companion dogs}, author = {Jacob Ryave and Amanda Erickson Coleman}, journal = {Journal of Veterinary Science}, year = {2025}, doi = {10.4142/jvs.25219}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings